Incidence rate (per 100 person-years)   Hazard ratio
(95% CI)		 P value
NOAC Reference
Apixaban vs warfarin (reference) n = 18,181 n = 18,181      
Stroke/SE† 1.3 1.8
 
 0.63 (0.49-0.82) .001
Ischemic 1.0 1.2
 
 0.78 (0.63-0.96) .017
Hemorrhagic 0.2 0.6
 
 0.37 (0.18-0.77) .007
Major bleeding‡ 4.1 6.8
 
 0.54 (0.49-0.61) <.001
GI bleeding 2.0 3.2
 
 0.54 (0.46-0.63) <.001
ICH 0.4 1.0
 
 0.38 (0.25-0.56) <.001
Dabigatran vs warfarin (reference) n = 6646 n = 6646
 
    
Stroke/SE† 1.6 1.3
 
 1.23 (0.90-1.67) .194
Ischemic 1.3 0.9
 
 1.53 (1.03-2.26) .035
Hemorrhagic 0.2 0.4
 
 0.47 (0.21-1.06) .070
Major bleeding‡ 4.2 5.5
 
 0.75 (0.63-0.91) .003
GI bleeding 2.6 2.7
 
 0.97 (0.76-1.25 .810
ICH 0.4 0.5
 
 0.75 (0.40-1.41) .368
Rivaroxaban vs warfarin (reference) n = 22,053 n = 22,053
 
    
Stroke/SE† 1.4 1.6
 
 0.84 (0.72-0.98) .029
Ischemic 1.1 1.1
 
 0.93 (0.78-1.11) .418
Hemorrhagic 0.2 0.5
 
 0.53 (0.37-0.78) .001
Major bleeding‡ 6.7 6.5
 
 1.02 (0.90-1.17) .750
GI bleeding 3.9 3.1
 
 1.25 (1.11-1.41) <.001
ICH 0.4 0.8
 
 0.49 (0.34-0.70) <.001
0.0
0.5
1.0
1.5
2.0
Favors NOACs
Favors warfarin

No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs versus DOACs.

Appearance of plotted data may be altered when zoom greater than 150% is applied;
refer to values in tables for context when view is zoomed.

1|2|3|4|5